{"id":3154,"date":"2014-11-20T15:00:00","date_gmt":"2014-11-20T15:00:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/xvivo-far-vinnova-finansiering-for-cancerforskning\/"},"modified":"2014-11-20T15:00:00","modified_gmt":"2014-11-20T15:00:00","slug":"xvivo-far-vinnova-finansiering-for-cancerforskning","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/","title":{"rendered":"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong>Vinnova har valt att finansiera ett av XVIVO Perfusions projekt inom In Vivo Lung Perfusion (IVLP) genom forsknings- och innovationsprogrammet Forska &amp; V\u00e4x.<\/strong><\/div>\n<\/p>\n<p><span>XVIVO Perfusion har idag en ledande internationell position inom Ex Vivo Lung Perfusion (EVLP) med STEEN Solution\u2122 och ser nu en m\u00f6jlighet att anv\u00e4nda den etablerade plattformen till att expandera inom In Vivo Lung Perfusion (IVLP). F\u00f6rstudien, som Vinnova valt att finansiera, syftar till att utv\u00e4rdera m\u00f6jligheten att behandla lungcancer genom att isolera lungan in situ och perfundera med kemoterapi. Metoden g\u00e5r ut p\u00e5 att sk\u00f6lja isolerade lungor i kroppen med STEEN Solution\u2122 som fungerar som b\u00e4rare av cellgifter. Hypotesen \u00e4r att IVLP med STEEN Solution\u2122 som perfusat kommer att leda till f\u00e4rre biverkningar.<\/span><\/p>\n<\/p>\n<p><span>&#34;IVLP kan visa sig vara revolutionerande f\u00f6r behandling av lungcancer. F\u00f6rstudien g\u00f6rs tillsammans med en av de ledande klinikerna i Europa och v\u00e5r m\u00e5ls\u00e4ttning \u00e4r att skapa optimala f\u00f6ruts\u00e4ttningar f\u00f6r att, i n\u00e4sta steg genomf\u00f6ra en klinisk multi-center studie, &#34;s\u00e4ger Petra Apell, regionchef p\u00e5 XVIVO Perfusion. <\/span><\/p>\n<\/p>\n<p><span>Ett problem inom behandling av vissa former av lungcancer \u00e4r att de cellgifter som anv\u00e4nds vid behandlingen riskerar att skada andra organ i kroppen. Genom att isolera lungan och bara behandla lungan med cellgifter kan skadliga biverkningar begr\u00e4nsas. Eftersom STEEN Solution\u2122 m\u00f6jligg\u00f6r perfusion av lungan kan l\u00f6sningen anv\u00e4ndas som b\u00e4rare av cellgifter i den isolerade lungan.<\/span><\/p>\n<\/p>\n<p><span>&#34;Vi \u00e4r mycket glada \u00f6ver att Vinnova har beslutat att st\u00f6dja detta projekt ekonomiskt. IVLP med hj\u00e4lp av STEEN Solution\u2122 som b\u00e4rare av cancerl\u00e4kemedel har god potential att minska biverkningarna och kan kanske till och med \u00f6ka \u00f6verlevnaden f\u00f6r vissa patienter med lungcancer&#34;, s\u00e4ger Dr Magnus Nilsson, VD f\u00f6r XVIVO Perfusion.<\/span><\/p>\n<\/p>\n<p><span>G\u00f6teborg 20 november 2014<br \/> XVIVO Perfusion AB (publ)<br \/> Magnus Nilsson <br \/> CEO<\/span><\/p>\n<div class=\"mfn-footer\">\n<p><span>F\u00f6r ytterligare information, v\u00e4nligen kontakta: <\/span><\/p>\n<p><span>Christoffer Rosenblad, CFO, tel: 031-788 21 59, e-post: <a href=\"mailto:christoffer.rosenblad@xvivperfusion.com\" rel=\"nofollow\">christoffer.rosenblad@xvivoperfusion.com<\/a><br \/>F\u00f6r ytterligare information om XVIVO Perfusions verksamhet h\u00e4nvisas till bolagets hemsida, <a href=\"http:\/\/www.xvivoperfusion.com\" rel=\"nofollow\">www.xvivoperfusion.com<\/a><\/span><\/p>\n<p><span>XVIVO Perfusion\u00a0\u00e4r skyldigt att offentligg\u00f6ra informationen i detta pressmeddelande enligt lagen om v\u00e4rdepappersmarknaden och\/eller lagen om handel med finansiella instrument. Informationen l\u00e4mnades f\u00f6r publicering den\u00a020 november 2014 kl. 16:00.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Vinnova har valt att finansiera ett av XVIVO Perfusions projekt inom In Vivo Lung Perfusion (IVLP) genom forsknings- och innovationsprogrammet&#8230;<\/p>\n","protected":false},"template":"","class_list":["post-3154","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-other","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir","mfn-news-tag-mfn-lang-sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning - XVIVO\" \/>\n<meta property=\"og:description\" content=\"Vinnova har valt att finansiera ett av XVIVO Perfusions projekt inom In Vivo Lung Perfusion (IVLP) genom forsknings- och innovationsprogrammet...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-vinnova-finansiering-for-cancerforskning\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-vinnova-finansiering-for-cancerforskning\\\/\",\"name\":\"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2014-11-20T15:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-vinnova-finansiering-for-cancerforskning\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-vinnova-finansiering-for-cancerforskning\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/xvivo-far-vinnova-finansiering-for-cancerforskning\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/","og_locale":"en_US","og_type":"article","og_title":"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning - XVIVO","og_description":"Vinnova har valt att finansiera ett av XVIVO Perfusions projekt inom In Vivo Lung Perfusion (IVLP) genom forsknings- och innovationsprogrammet...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/","name":"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2014-11-20T15:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/xvivo-far-vinnova-finansiering-for-cancerforskning\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"XVIVO f\u00e5r Vinnova\u2013finansiering f\u00f6r cancerforskning"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3154","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3154"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}